The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Open accessAbstract
mutation frequency, pancreatic ductal adenocarcinoma (PDAC) is considered the most RAS-addicted of all cancers. We review the role of KRAS as a driver and therapeutic target in PDAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This high prevalence is significant as it makes PDAC arguably the most RAS-addicted cancer, with substantial experimental evidence that mutant KRAS is essential for its growth [107].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [107]
The cited source says what the claim attributes to it.
In the citing paper
“In particular, the KRAS isoform is mutated in 84% of all RAS-mutant cancers, with a near 100% mutation frequency in PDAC.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [107]
In the citing paper
“The majority of KRAS mutations are at codon 12, with the highest prevalence of G12D mutation (35%), followed by G12V (20–30%), G12R (10–20%), Q61 (~5%), G12C (1–2%), and other rare muations9–12.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [9]
In the citing paper
“In pancreatic cancer, KRAS mutation is often the initiating genetic event leading to pancreatic intraepithelial neoplasms. Carcinogenesis and metastasis are stimulated by acquiring other mutations such as p53 (64%), SMAD4 (21%), and CDKN2A (17%) [63].”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [63]
In the citing paper
“A number of highly selective and potent inhibitors have been developed against kinases in the Ras signaling network particularly those in the MAPK and PI3K/mTOR pathways (9, 12).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [12]
In the citing paper
“the KRASG12C allele occurs in only 1.6% of PDAC cases, whereas the KRASG12D allele is present in greater than 40%, followed in frequency by KRASG12V and KRASG12R mutations74.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 4×
“Further, wholeexome deep-sequencing data of pancreatic cancer patients shows that 93% of the rare PIK3CA mutations co-occur with aKRASmutation, suggesting activated KRAS alone is not sufficient to effectively activate PI3K (Jones et al. 2008; Biankin et al. 2012; Sausen et al. 2015; Waddell et al. 2015; Witkiewicz et…”
BackgroundMethodInfluentialA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Flagged first, then by citations
Cited by
Sorted by citations
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Bryant, K. L., Stalnecker, C. A., Zeitouni, D., Klomp, J. E., Peng, S., Tikunov, A. P., Gunda, V., Pierobon, M., Waters, A. M., George, S. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0368-8 · Cited by 692
Self-citationDai, E., Han, L., Liu, J., Xie, Y., Kroemer, G., Klionsky, D. J., Zeh, H. J., Kang, R., Wang, J., & Tang, D. (2020) · Autophagy · doi:10.1080/15548627.2020.1714209 · Cited by 613
G-quadruplexes: a promising target for cancer therapy
Kosiol, N., Juranek, S., Brossart, P., Heine, A., & Paeschke, K. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01328-4 · Cited by 548
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Strickler, J. H., Satake, H., George, T. J., Yaeger, R., Hollebecque, A., Garrido-Laguna, I., Schuler, M., Burns, T. F., Coveler, A. L., Falchook, G. S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2208470 · Cited by 527
Dai, E., Han, L., Liu, J., Xie, Y., Zeh, H. J., Kang, R., Bai, L., & Tang, D. (2020) · Nature Communications · doi:10.1038/s41467-020-20154-8 · Cited by 440
Therapeutic developments in pancreatic cancer
Hu, Z., & O'Reilly, E. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 438
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Nevala-Plagemann, C., Hidalgo, M. M., & Garrido‐Laguna, I. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0281-6 · Cited by 403
Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer
Kemp, S. B., Cheng, N., Markosyan, N., Sor, R., Kim, I.-K., Hallin, J., Shoush, J., Quinones, L., Brown, N. V., Bassett, J. B., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1066 · Cited by 370
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
Achieving clinical success with BET inhibitors as anti-cancer agents
Shorstova, T., Foulkes, W. D., & Witcher, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01321-0 · Cited by 367
Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0027 · Cited by 343
Molecular epidemiology and diagnostics of KRAS mutations in human cancer
Timar, J., & Kashofer, K. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09915-5 · Cited by 334
Principe, D. R., Underwood, P. W., Korc, M., Trevino, J. G., Munshi, H. G., & Rana, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.688377 · Cited by 273
Translational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 255
Yi, M., Nissley, D. V., McCormick, F. P., & Stephens, R. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-66986-8 · Cited by 235
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
Hobbs, G. A., Baker, N. M., Miermont, A. M., Thurman, R. D., Pierobon, M., Tran, T. H., Anderson, A. O., Waters, A. M., Diehl, J. N., Papke, B., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1006 · Cited by 231
Self-citationTargeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
Koikawa, K., Kibe, S., Suizu, F., Sekino, N., Kim, N., Manz, T. D., Pinch, B. J., Akshinthala, D., Verma, A., Gaglia, G., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.020 · Cited by 243
The KRAS-G12C inhibitor: activity and resistance
Liu, J., Kang, R., & Tang, D. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00383-9 · Cited by 229
The pancreatic cancer genome revisited
Hayashi, A., Hong, J., & Iacobuzio-Donahue, C. A. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00463-z · Cited by 211
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Wasko, U. N., Jiang, J., Dalton, T. C., Curiel-Garcia, A., Edwards, A. C., Wang, Y., Lee, B., Orlen, M., Tian, S., Stalnecker, C. A., et al. (2024) · Nature · doi:10.1038/s41586-024-07379-z · Cited by 209
Self-citationThe path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 198
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
Vaseva, A. V., Blake, D. R., Gilbert, T. S. K., Ng, S., Hostetter, G. H., Azam, S. H., Ozkan‐Dagliyan, I., Gautam, P., Bryant, K. L., Pearce, K. H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.001 · Cited by 187
Self-citationLee, J. K., Sivakumar, S., Schrock, A. B., Madison, R., Fabrizio, D., Gjoerup, O., Ross, J. S., Frampton, G. M., Napalkov, P., Montesion, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00334-z · Cited by 187
Autophagy as a therapeutic target in pancreatic cancer
Piffoux, M., Eriau, E., & Cassier, P. A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01039-5 · Cited by 189
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer
Goodwin, C. M., Waters, A. M., Klomp, J. E., Javaid, S., Bryant, K. L., Stalnecker, C. A., Drizyte-Miller, K., Papke, B., Yang, R., Amparo, A. M., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-0391 · Cited by 168
Self-citationDrugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
Mao, Z., Xiao, H., Shen, P., Yang, Y., Xue, J., Yang, Y., Shang, Y., Zhang, L., Li, X., Zhang, Y., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00368-w · Cited by 158
The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance
Biancur, D. E., & Kimmelman, A. C. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.011 · Cited by 152
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Wei, D., Wang, L., Zuo, X., Maitra, A., & Bresalier, R. S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2098 · Cited by 177
Oncogene-like addiction to aneuploidy in human cancers
Girish, V., Lakhani, A. A., Thompson, S. L., Scaduto, C. M., Brown, L. M., Hagenson, R. A., Sausville, E. L., Mendelson, B. E., Kandikuppa, P. K., Lukow, D. A., et al. (2023) · Science · doi:10.1126/science.adg4521 · Cited by 148
Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy
Trimpont, M. V., Peeters, E., Visser, Y. D., Schalk, A. M., Mondelaers, V., Moerloose, B. D., Lavie, A., Lammens, T., Goossens, S., & Vlierberghe, P. V. (2022) · Cancers · doi:10.3390/cancers14040902 · Cited by 143
Udayasuryan, B., Nguyen, T. T. D., Nguyen, T. T. D., Umaña, A., Roberts, L. M., Sobol, P., Jones, S. D., Munson, J. M., Slade, D. J., & Verbridge, S. S. (2022) · Science Signaling · doi:10.1126/scisignal.abn4948 · Cited by 152
Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0158 · Cited by 150
Ling, C.-W., Miao, Z., Xiao, M.-L., Zhou, H., Jiang, Z., Fu, Y., Xiong, F., Zuo, L.-S.-Y., Liu, Y.-P., Wu, Y.-Y., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab492 · Cited by 138
Hu, C.-M., Tien, S.-C., Hsieh, P.-K., Jeng, Y.-M., Chang, M.-C., Chang, Y.-T., Chen, Y.-J., Chen, Y.-J., Lee, E. Y.-H. P., & Lee, W.-H. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.005 · Cited by 123
Chibaya, L., Murphy, K. C., DeMarco, K. D., Gopalan, S., Liu, H., Parikh, C. N., Lopez-Diaz, Y., Faulkner, M., Li, J., Morris, J. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00553-8 · Cited by 138
Yang, Z., Lariviere, M. J., Ko, J., Till, J. E., Christensen, T. E., Yee, S. S., Black, T. A., Tien, K., Lin, A. A., Shen, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3313 · Cited by 130
Li, R., Ng, T. S. C., Wang, S. J., Prytyskach, M., Rodell, C. B., Mikula, H., Köhler, R. H., Garlin, M. A., Lauffenburger, D. A., Parangi, S., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00897-1 · Cited by 130
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Klomp, J. A., Klomp, J. E., Stalnecker, C. A., Bryant, K. L., Edwards, A. C., Drizyte‐Miller, K., Hibshman, P. S., Diehl, J. N., Lee, Y. S., Morales, A. J., et al. (2024) · Science · doi:10.1126/science.adk0775 · Cited by 139
Self-citationCDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer
Huang, J., Chen, P., Liu, K., Liu, J., Zhou, B., Wu, R., Qiu, P., Liu, Z., Li, C., Kroemer, G., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-320441 · Cited by 120
Huang, L., Desai, R., Conrad, D. N., Leite, N. C., Akshinthala, D., Lim, C. M., González, R. S., Muthuswamy, L. B., Gartner, Z. J., & Muthuswamy, S. K. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.03.022 · Cited by 119
Cell of origin influences pancreatic cancer subtype
Flowers, B. M., Xu, H., Mulligan, A. S., Hanson, K. J., Seoane, J. A., Vogel, H., Curtis, C., Wood, L. D., & Attardi, L. D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0633 · Cited by 118
Mechanisms of Resistance to KRASG12C Inhibitors
Dunnett-Kane, V., Nicola, P. A., Blackhall, F. H., & Lindsay, C. R. (2021) · Cancers · doi:10.3390/cancers13010151 · Cited by 122
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 119
Epithelial and stromal co-evolution and complicity in pancreatic cancer
Hingorani, S. R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00530-w · Cited by 108
Brown, W. S., McDonald, P. C., Nemirovsky, O., Awrey, S., Chafe, S. C., Schaeffer, D. F., Li, J., Renouf, D. J., Stanger, B. Z., & Dedhar, S. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100131 · Cited by 111
Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
Sun, Y., Yu, X., Wang, X., Yuan, K., Wang, G., Hu, L., Zhang, G., Pei, W., Wang, L., Sun, C., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.023 · Cited by 116
Therapeutic targeting of RAS: New hope for drugging the “undruggable”
Khan, I., Rhett, J. M., & O’Bryan, J. P. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118570 · Cited by 111
Single-EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer
Ferguson, S. W., Yang, K. S., Zelga, P. J., Liss, A. S., Carlson, J., del Castillo, C. F., & Weissleder, R. (2022) · Science Advances · doi:10.1126/sciadv.abm3453 · Cited by 110
Lorthiois, E., Gerspacher, M., Beyer, K. S., Vaupel, A., Leblanc, C., Stringer, R., Weiss, A., Wilcken, R., Guthy, D. A., Lingel, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01438 · Cited by 110
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110
Ozkan‐Dagliyan, I., Diehl, J. N., George, S. D., Schaefer, A., Papke, B., Klotz‐Noack, K., Waters, A. M., Goodwin, C. M., Gautam, P., Pierobon, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107764 · Cited by 104
Self-citationRevealing macropinocytosis using nanoparticles
Means, N., Elechalawar, C. K., Chen, W. R., Bhattacharya, R., & Mukherjee, P. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100993 · Cited by 109
Tokumaru, Y., Oshi, M., Katsuta, E., Yan, L., Satyananda, V., Matsuhashi, N., Futamura, M., Akao, Y., Yoshida, K., & Takabe, K. (2020) · PubMed Central · Cited by 105
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
Luchini, C., Paolino, G., Mattiolo, P., Piredda, M. L., Cavaliere, A., Gaule, M., Melisi, D., Salvia, R., Malleo, G., Shin, J. I., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01732-6 · Cited by 105
Role and Function of O-GlcNAcylation in Cancer
Lee, J. B., Pyo, K., & Kim, H. R. (2021) · Cancers · doi:10.3390/cancers13215365 · Cited by 103
Ferreira, A. I., Pereira, F. D. S., Reis, C. A., Oliveira, M. J., Sousa, M. J., & Preto, A. (2022) · Cells · doi:10.3390/cells11142183 · Cited by 111
Targeting KRAS in pancreatic cancer
Stickler, S., RATH, B., & Hamilton, G. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.045356 · Cited by 105
Qin, Q., Yu, R., Eriksson, J., Tsai, H., & Zhu, H. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216859 · Cited by 102
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00505-0 · Cited by 93
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer
Pecoraro, C., Faggion, B., Balboni, B., Carbone, D., Peters, G. J., Diana, P., Assaraf, Y. G., & Giovannetti, E. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100779 · Cited by 92
Zhang, A. M. Y., Xia, Y. H., Lin, J. S. H., Chu, K., Wang, W. C. K., Ruiter, T. J. J., Yang, J. C. C., Chen, N., Chhuor, J., Patil, S., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.003 · Cited by 91
Pei, Y., Liang, C., Huang, Y., Wang, J., Feng, J., Xu, M., Chen, Y., Song, Q., Jiang, G., Gu, X. Q., et al. (2019) · Small · doi:10.1002/smll.201900631 · Cited by 91
CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
Harvey, J. B., Phan, L. H., Villarreal, O. E., & Bowser, J. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00508 · Cited by 88
Drugging “undruggable” genes for cancer treatment: Are we making progress?
Duffy, M. J., & Crown, J. P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33197 · Cited by 86
Application of engineered extracellular vesicles for targeted tumor therapy
Zhang, F., Guo, J. J., Zhang, Z., Duan, M., Wang, G., Qian, Y., Zhao, H., Yang, Z., & Jiang, X. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00798-y · Cited by 92
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer
Klomp, J. E., Diehl, J. N., Klomp, J. A., Edwards, A. C., Yang, R., Morales, A. J., Taylor, K. E., Drizyte-Miller, K., Bryant, K. L., Schaefer, A., et al. (2024) · Science · doi:10.1126/science.adk0850 · Cited by 83
Self-citationHalbrook, C. J., Thurston, G., Boyer, S., Anaraki, C., Jiménez, J. A., McCarthy, A., Steele, N. G., Kerk, S. A., Hong, H. S., Lin, L., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00463-1 · Cited by 80
Lanfredini, S., Thapa, A., & O’Neill, E. E. (2019) · Biochemical Society Transactions · doi:10.1042/bst20170521 · Cited by 78
Advances in Pancreatic Ductal Adenocarcinoma Treatment
Anderson, E. M., Thomassian, S., Gong, J., Hendifar, A. E., & Osipov, A. (2021) · Cancers · doi:10.3390/cancers13215510 · Cited by 78
Profiling of microglia nodules in multiple sclerosis reveals propensity for lesion formation
van den Bosch, A. M. R., van der Poel, M., Fransen, N. L., Vincenten, M. C. J., Bobeldijk, A. M., Jongejan, A., Engelenburg, H. J., Moerland, P. D., Smolders, J., Huitinga, I., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46068-3 · Cited by 77
Natu, J., & Nagaraju, G. P. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216382 · Cited by 73
Blake, D. R., Vaseva, A. V., Hodge, R. G., Kline, M. P., Gilbert, T. S. K., Tyagi, V., Huang, D., Whiten, G. C., Larson, J. E., Wang, X., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aav7259 · Cited by 71
Self-citationA comprehensive review of pancreatic cancer and its therapeutic challenges
Jiang, S., Fagman, J. B., Ma, Y., Liu, J., Vihav, C., Engström, C., Liu, B., & Chen, C. (2022) · Aging · doi:10.18632/aging.204310 · Cited by 76
Establishment of Pancreatic Organoids from Normal Tissue and Tumors
Driehuis, E., Gracanin, A., Vries, R. G. J., Clevers, H. C., & Boj, S. F. (2020) · STAR Protocols · doi:10.1016/j.xpro.2020.100192 · Cited by 76
Developing effective combination therapy for pancreatic cancer: An overview
Miller, A. L., Garcia, P. L., & Yoon, K. J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104740 · Cited by 73
The rise of covalent proteolysis targeting chimeras
Gabizon, R., & London, N. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.12.003 · Cited by 71
Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors
Dietz, M. S., Sutton, T. L., Walker, B. S., Gast, C. E., Zarour, L. R., Sengupta, S. K., Swain, J. R., Eng, J. R., Parappilly, M. S., Limbach, K. E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93053-7 · Cited by 70
Rangel, M., Kong, J., Bhatt, V. D., Khayati, K., & Guo, J. Y. (2021) · FEBS Journal · doi:10.1111/febs.16125 · Cited by 76
KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications
Pereira, F. D. S., Ferreira, A. I., Reis, C. A., Sousa, M. J., Oliveira, M. J., & Preto, A. (2022) · Cells · doi:10.3390/cells11030398 · Cited by 78
Pharmacokinetic tuning of protein–antigen fusions enhances the immunogenicity of T-cell vaccines
Mehta, N. K., Pradhan, R., Soleimany, A. P., Moynihan, K. D., Rothschilds, A. M., Momin, N., Rakhra, K., Mata-Fink, J., Bhatia, S. N., Wittrup, K. D., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0563-4 · Cited by 68
Sun, C., Ye, Y., Tan, Z., Liu, Y., Li, Y., Hu, W., Liang, K., Egranov, S. D., Huang, L. A., Zhang, Z., et al. (2023) · Science Advances · doi:10.1126/sciadv.add6995 · Cited by 67
Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer
Chiang, C.-L., Ma, Y., Hou, Y.-C., Pan, J., Chen, S.-Y., Chien, M.-H., Zhang, Z.-X., Hsu, W.-H., Wang, X., Zhang, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42402-3 · Cited by 63
Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers’ Discovery
Brancaccio, M., Natale, F., Falco, G., & Angrisano, T. (2019) · Genes · doi:10.3390/genes11010014 · Cited by 65
Pramanik, S., Chen, Y., Song, H., Khutsishvili, I., Marky, L. A., Ray, S., Natarajan, A., Singh, P. K., & Bhakat, K. K. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac172 · Cited by 60
Evan, T., Wang, V. M.-Y., & Behrens, A. (2022) · Oncogene · doi:10.1038/s41388-022-02448-x · Cited by 66
Linking Metabolic Reprogramming, Plasticity and Tumor Progression
Shuvalov, O., Daks, A., Fedorova, O., Petukhov, A., & Barlev, N. (2021) · Cancers · doi:10.3390/cancers13040762 · Cited by 63
Kalluri, V. S., Smaglo, B. G., Mahadevan, K. K., Kirtley, M. L., McAndrews, K. M., Mendt, M., Yang, S., Maldonado, A. S., Sugimoto, H., Salvatierra, M. E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63718-2 · Cited by 70
Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy
Cuomo, F., Altucci, L., & Cobellis, G. (2019) · Cancers · doi:10.3390/cancers11101465 · Cited by 64
hnRNP A/B Proteins: An Encyclopedic Assessment of Their Roles in Homeostasis and Disease
Thibault, P. A., Ganesan, A., Kalyaanamoorthy, S., Clarke, J.-P. W. E., Salapa, H. E., & Levin, M. C. (2021) · Biology · doi:10.3390/biology10080712 · Cited by 59
Protease-controlled secretion and display of intercellular signals
Vlahos, A. E., Kang, J., Aldrete, C. A., Zhu, R., Chong, L. S., Elowitz, M. B., & Gao, X. J. (2022) · Nature Communications · doi:10.1038/s41467-022-28623-y · Cited by 64
A prime editor mouse to model a broad spectrum of somatic mutations in vivo
Ely, Z. A., Mathey‐Andrews, N., Naranjo, S., Gould, S. I., Mercer, K. L., Newby, G. A., Cabana, C. M., Rideout, W. M., Jaramillo, G. C., Khirallah, J., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01783-y · Cited by 63
Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer—Advances and Challenges
Seyhan, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713340 · Cited by 63
McDaid, W. J., Greene, M. K., Johnston, M. C., Pollheimer, E., Smyth, P., McLaughlin, K., Van Schaeybroeck, S., Straubinger, R. M., Longley, D. B., & Scott, C. J. (2019) · Nanoscale · doi:10.1039/c9nr07257h · Cited by 58
Ferino, A., Nicoletto, G., D’Este, F., Zorzet, S., Lago, S., Richter, S. N., Tikhomirov, A. S., Shchekotikhin, A. E., & Xodo, L. E. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01577 · Cited by 60
Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer
Regel, I., Mayerle, J. V., & Mukund, M. U. (2020) · Cancers · doi:10.3390/cancers12041024 · Cited by 61
Kumarasamy, V. M., Frangou, C. G., Wang, J., Wan, Y., Dynka, A., Rosenheck, H. R., Dey, P., Abel, E. V., Knudsen, E. S., & Witkiewicz, A. K. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2504 · Cited by 57
Orlen, M., Vostrejs, W. P., Sor, R., McDevitt, J. C., Kemp, S. B., Kim, I., Kramer, A. B., Shifrin, N. T., Markosyan, N., Clendenin, C., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1475 · Cited by 64
NF-κB and Pancreatic Cancer; Chapter and Verse
Silke, J., & O’Reilly, L. A. (2021) · Cancers · doi:10.3390/cancers13184510 · Cited by 55
Metadata
- Authors
- Waters, A. M., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-12-11
- Volume
- 8
- Issue
- 9
- Pages
- a031435
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC5995645
- OpenAlex
- W2771729549
- Cited by
- 875
- References
- 109
- Citations by year
- 2026: 73 · 2025: 112 · 2024: 121 · 2023: 118 · 2022: 153 · 2021: 157 · 2020: 98 · 2019: 35 · 2018: 8
- Type
- posted content
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- Funders
- U.S. Department of Defense
- American Association for Cancer Research
- Pancreatic Cancer Action Network
- Lustgarten Foundation
- National Science Council
- National Institutes of Health (5r01ca042978-30)
- National Cancer Institute (CA042978, CA203657, P01CA203657, R01CA175747, T32CA009156, P50CA196510, R01-CA042978, CA199235, U01CA199235, CA196510, P30CA016086)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS, pancreatic ductal adenocarcinoma, pancreatic cancer, driver mutations, therapeutic target, KRAS inhibitors
- MeSH terms
- Adenocarcinoma, Animals, Humans, Mutation, Signal Transduction, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal, Protein Kinase Inhibitors, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
